Bettiol, Alessandra
Alibaz-Oner, Fatma
Direskeneli, Haner http://orcid.org/0000-0003-2598-5806
Hatemi, Gulen
Saadoun, David
Seyahi, Emire
Prisco, Domenico
Emmi, Giacomo http://orcid.org/0000-0001-9575-8321
Article History
Accepted: 21 November 2022
First Online: 21 December 2022
Competing interests
: F.A.-O. has received honoraria, consulting or speaker fees from Pfizer, AbbVie and Amgen. H.D. has received honoraria, consulting and speaker fees from AbbVie, Pfizer, Roche, Novartis, UCB Pharma, Amgen and Celltrione. G.E. has received honoraria and speaker fees from Novartis, Roche, Sobi, AstraZeneca, Boehringer Ingelheim, Janssen, Sanofi and GSK. G.H. has received research grants, honoraria and speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Janssen, Novartis, Pfizer, Silk Road Therapeutics and UCB Pharma. D.S. has received honoraria, consulting or speaker fees from Novartis, Amgen, Celltrion, Celgene, Roche Chugai, Viatris, Sanofi and AbbVie. E.S. has received honoraria, consulting or speaker fees from Novartis, Pfizer and AbbVie. A.B. and D.P. declare no competing interests.